CA-SYSDIG
7.3.2024 16:01:30 CET | Business Wire | Press release
Sysdig, the leader in cloud security powered by runtime insights, today announced that the company was named a Strong Performer — one of only two vendors to receive the recognition — in Gartner Peer Insights “Voice of the Customer” for Cloud Security Posture Management (CSPM) Tools. Sysdig is the only cloud security platform to receive the maximum of five stars in the report, which was derived directly from verified customer feedback, and synthesizes reviews and ratings received as of November 30, 2023.
In addition to receiving the highest overall rating, Sysdig received top marks in each category:
- Product Capabilities: 4.9/5
- Sales Experience: 4.9/5
- Deployment Experience: 4.9/5
- Support Experience: 5/5
As the cloud landscape continues to evolve, Sysdig is at the forefront of cloud security innovation, offering active cloud risk prioritization, vulnerability management, and compliance solutions that go beyond traditional static checks. The company's dedication to providing comprehensive visibility and robust security measures has garnered widespread acclaim from its user base, as it believes is evidenced by its exceptional ratings in the Gartner “Voice of the Customer” report.
"Customers demand and deserve excellence, and we are thrilled to receive such high praise in the Gartner Voice of the Customer report. We believe a 5 out of 5 rating underscores our commitment to CISOs and boards to keep their cloud environment safe," said Knox Anderson, SVP of Product Management at Sysdig. "The industry knows Sysdig as the leader in CNAPP, and now they can feel confident knowing how much our customers love our CSPM solution."
Read the full “Voice of the Customer” report for Cloud Security Posture Management Tools.
Sysdig Customers Praise Productivity Driven by Runtime Insights
The cloud is a dynamic environment where new risks and threats can appear at any time. Most CSPM solutions perform periodic scanning, which only shows static risk and leaves visibility gaps for attackers to exploit. Sysdig empowers organizations to strengthen their cloud security posture through unified findings with active risk prioritization, agentless scanning, attack path analysis, inventory, and real-time security posture checks. Using runtime insights, Sysdig offers unparalleled visibility into active cloud risk, such as real-time configuration changes, suspicious user activity, in-use permission and packages, and workload threats.
By prioritizing active cloud risk, security teams can work more productively by reducing alert fatigue and focusing on addressing the most imminent active threats in their cloud environment. In essence, Sysdig strengthens organizations’ approaches to cloud security posture management, from risk prioritization and vulnerability management to proactive threat detection and compliance, giving them peace of mind that their assets are protected when cloud attacks can happen in a matter of minutes.
Customer feedback highlighted Sysdig's unique approach to CSPM, with users praising the platform for its comprehensive cloud-native security features and ability to improve incident response times. But CSPM is only one part of the Sysdig cloud-native application protection platform (CNAPP), which combines CSPM with cloud workload protection, cloud infrastructure entitlement management, and detection and response in a single security platform to provide customers with end-to-end coverage, from prevention to defense. With Sysdig, organizations can mitigate security issues fast, bolster operational efficiency across multi-cloud environments, and protect the entire software development life cycle.
What our Customers are Saying in Gartner Peer Insights
“I’m genuinely impressed with the level of real-time security posture checks [Sysdig] brings to our cloud infrastructure. The solution has proven to be an invaluable asset in ensuring the safety of our cloud-native application and data.” [Read the full review here]
- Director of Strategic Initiatives; Software Company
“Sysdig CSPM provides unmatched insight and fortified security for cloud-native infrastructure with state-of-art technology. Powered by Falco, it offers comprehensive visibility, empowering businesses to monitor and safeguard cloud assets efficiently…” [Read the full review here]
- VP, IT Security and Risk Management; Financial Company
“Our adoption of Sysdig CSPM was fueled by the growing complexity of our cloud environment. As our presence expanded rapidly, robust security and compliance became imperative. We required a unified solution that could monitor, detect, and manage risk across both AWS and GCP.” [Read the full review here]
- Director of Strategic Initiatives; Software Company
“Since implementing Sysdig CSPM, our incident response time has drastically improved, allowing us to mitigate security issues promptly.” [Read the full review here]
- Information Security Officer; IT Services Company
Gartner Peer Insights content consists of the opinions of individual end users based on their own experiences, and should not be construed as statements of fact, nor do they represent the views of Gartner or its affiliates. Gartner does not endorse any vendor, product, or service depicted in this content nor makes any warranties, expressed or implied, with respect to this content, about its accuracy or completeness, including any warranties of merchantability or fitness for a particular purpose.
GARTNER is a registered trademark and service mark of Gartner, Inc. and/or its affiliates in the U.S. and internationally, PEER INSIGHTS is a registered trademark of Gartner, Inc. and/or its affiliates and both are used herein with permission. All rights reserved.
This graphic was published by Gartner, Inc. as part of a larger research document and should be evaluated in the context of the entire document. The Gartner document is available here.
Resources
- Visit Sysdig’s page on Gartner Peer Insights.
- Read Sysdig's blog, “Customers Rate Sysdig 5 Out of 5 in Gartner ‘Voice of the Customer’ for Cloud Security Posture Management Tools” to learn more about the announcement.
- Watch “Sysdig. Secure Every Second.” to learn more about the company.
About Sysdig
In the cloud, every second counts. Attacks move at warp speed, and security teams must protect the business without slowing it down. Sysdig stops cloud attacks in real time, instantly detecting changes in risk with runtime insights and open source Falco. Sysdig correlates signals across cloud workloads, identities, and services to uncover hidden attack paths and prioritize real risk. From prevention to defense, Sysdig helps enterprises focus on what matters: innovation. Sysdig. Secure Every Second.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240307640009/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
